与不适当的静脉注射质子抑制剂在住院患者中的使用相关的预测因素:一项案例对照研究
Niveen Khoury1, David Stepensky2, Naim Abu Freha3
1Pharmacy Department, EMMS Nazareth Hospital, Nazareth 16100, Israel.
静脉注射的质子抑制剂 (PPI) 的不适当使用仍然很常见. 诸如充血性心力衰竭和外科医生的处方等因素会增加风险,突出需要更好的IV PPI管理.
科学领域:
- 胃肠病学 胃肠病学
- 临床药房 临床药房
- 医院 医院 医疗 医疗 医疗 医疗
背景情况:
- 质子抑制剂 (PPI) 是与酸相关的胃肠道疾病的主要治疗方法.
- 静脉注射 (IV) PPI配方的使用在医院环境中显著增加.
研究的目的:
- 评估IV PPI处方的适当性.
- 确定与不适当的IV PPI使用相关的风险因素和临床结果.
主要方法:
- 一项回顾性病例控制研究分析了接受IVPPI的540名住院患者.
- 数据收集包括从入院到出院后3个月的患者记录.
- 评估了IVPPI使用的适当性和临床结果.
主要成果:
- 24%的患者 (130/540) 在指示,剂量或持续时间方面表现出不适当的IVPPI使用.
- 不适当使用与充血性心力衰竭 (OR 1.77) 和外科医生处方 (OR 1.53) 有关.
结论:
- 在临床实践中,不适当的IV PPI注射是普遍存在的.
- 不适当使用的预测因素包括充血性心力衰竭,晚年,抗凝剂/抗血栓使用和手术管理.
更多相关视频
03:05Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
05:32Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
Published on: September 21, 2015
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
